Scarica l'app Stockscreener
9.70
0.94%
0.09
Dopo l'orario di chiusura:
9.70
Precedente Chiudi:
$9.61
Aprire:
$9.825
Volume 24 ore:
1.68M
Relative Volume:
1.04
Capitalizzazione di mercato:
$862.92M
Reddito:
$71.64M
Utile/perdita netta:
$-294.57M
Rapporto P/E:
-2.8973
EPS:
-3.348
Flusso di cassa netto:
$-84.46M
1 W Prestazione:
-7.79%
1M Prestazione:
-14.16%
6M Prestazione:
+7.18%
1 anno Prestazione:
-5.73%
Intervallo 1D:
$9.60
$9.90
Intervallo di 1 settimana:
$9.57
$10.68
Portata 52W:
$7.3575
$13.90
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.70 | 862.92M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-01 | Iniziato | JP Morgan | Overweight |
| 2026-04-14 | Iniziato | Lake Street | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Neutral |
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes - GlobeNewswire
Caspian Therapeutics and Kura Oncology to host investor call By Investing.com - Investing.com
Caspian Therapeutics and Kura Oncology to Host Investor Webcast on Caspian Formation and KO-7246 Data from EASD Meeting - Quiver Quantitative
Caspian Therapeutics and Kura Oncology to Host Investor - GlobeNewswire
Kura Oncology (KURA) Stock Price, News & Analysis - Stock Titan
Kura Oncology Share PriceKURA, RNS News, Articles, Quotes, & Charts (NASDAQ:KURA) - Proactive financial news
Why Is KURA Stock Rallying 8% After-Hours? - Stocktwits
Kura Oncology Inc. Company & People | KUR - Barron's
Nine new hires get rights to buy 128,250 Kura shares, phased in over four years. - Stock Titan
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Kura Oncology, Inc. : JP Morgan Initiates Cov - Moomoo
Kura Oncology, Inc. (KURA) stock price, news, quote and history - uk.finance.yahoo.com
Kura Oncology, Inc. (KURA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Kura Oncology CCO Brian Powl sells over $345k in company stock - Investing.com
Kura Oncology SVP sells $48,360 of stock - Investing.com
Kura Oncology COO Kathleen Ford sells $111,930 in company stock - Investing.com
A tax-related sale followed stock vesting: Kura Oncology (KURA) executive sold 4,607 shares. - Stock Titan
One sale covered taxes; two followed a trading plan. Kura Oncology (KURA) executive sold 32,450 shares. - Stock Titan
Return on equity % of Kura Oncology, Inc. – HAN:KUR - TradingView
Kura Oncology, Inc. Earnings and Revenue – HAN:KUR - TradingView
Kura Oncology, Inc. Revenue Breakdown – HAN:KUR - TradingView
ETFs Investing in Kura Oncology, Inc. Stocks - TradingView
Kura Oncology, Inc. Earnings and Revenue – HAN:KUR - TradingView
After three earlier sales, a Kura Oncology (KURA) officer proposes another share sale - Stock Titan
After selling 12,448 shares, a Kura Oncology (KURA) officer proposes selling 28,802 more. - Stock Titan
Shares valued at $74,308.56 are proposed for sale by Kura Oncology (KURA) officer Kathleen Ford. - Stock Titan
An August sale of 31,487 stock units precedes another proposed sale by Kura Oncology (KURA) officer Teresa Bair. - Stock Titan
A planned $133,940 share sale at Kura Oncology (KURA) involves officer Mollie Leoni. - Stock Titan
Shares valued at $49,571 are in a proposed sale by Kura Oncology (KURA) officer Thomas James Doyle. - Stock Titan
Two sales, two reasons: Kura Oncology (KURA) medical chief sold shares to cover taxes and under a trading plan. - Stock Titan
A stock award triggers a tax-covering share sale by Kura Oncology (KURA) COO Kathleen Ford. - Stock Titan
A tax-related sale leaves Kura Oncology (KURA) legal chief with 187,002 shares. - Stock Titan
Form 144 KURA ONCOLOGY For: 25 September By Investing.com - Investing.com Canada
Shares from a stock option exercise are proposed for sale by a Kura Oncology (KURA) officer, valued at $224,514. - Stock Titan
Kura Oncology, Inc. (KURA) Stock Analysis: A Biotech Innovator with a 173% Potential Upside - DirectorsTalk Interviews
Kura Oncology (KURA) awards CFO 450,000 stock options - Stock Titan
Kura Oncology (KURA) CFO files initial ownership report with no trades - Stock Titan
Kura Oncology Maintains 49.2% Stake in Caspian Therapeutics Following $50M Series A Funding - Kalkine Media
Kura Spins Out Caspian With $50m To Test Menin Inhibition In Diabetes - insights.citeline.com
Kura assets flow to Caspian for cardiometabolic indications - BioWorld News
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - AOL.com
Kura Oncology Raises $50M for Cardiometabolic Subsidiary Caspian - minichart.com.sg
KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil - GuruFocus
Kura Oncology at cantor conference: rapid launch, wider ambitions - Investing.com India
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - Yahoo Finance
Kura Oncology, Inc. Enters into Contribution and License and Intercompany Services Agreement with Caspian Therapeutics, Inc - marketscreener.com
Kura Oncology Launches Caspian Therapeutics With $50 Million Funding - marketscreener.com
Kura Oncology Appoints Jennifer Fulk as New CFO - The Globe and Mail
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus - TipRanks
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes - The Manila Times
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kura Oncology Inc Azioni (KURA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KATHLEEN FORD | Officer |
Sep 29 '26 |
Proposed Sale |
10.61 |
3,668 |
38,917 |
0 |
| MOLLIE LEONI | Officer |
Sep 29 '26 |
Proposed Sale |
10.61 |
28,802 |
305,589 |
0 |
| BRIAN POWL | Officer |
Sep 29 '26 |
Proposed Sale |
10.61 |
15,430 |
163,712 |
0 |
| Powl Brian T. | Chief Commercial Officer |
Sep 29 '26 |
Sale |
10.75 |
15,430 |
165,852 |
136,819 |
| Leoni Mollie | Chief Medical Officer |
Sep 29 '26 |
Sale |
10.75 |
28,802 |
309,567 |
141,095 |
| FORD KATHLEEN | Chief Operating Officer |
Sep 29 '26 |
Sale |
10.75 |
3,668 |
39,437 |
142,986 |
| DOYLE THOMAS JAMES | Officer |
Sep 28 '26 |
Proposed Sale |
10.76 |
4,607 |
49,571 |
0 |
| FORD KATHLEEN | Officer |
Sep 28 '26 |
Proposed Sale |
10.76 |
6,906 |
74,309 |
0 |
| BAIR TERESA BROPHY | Officer |
Sep 28 '26 |
Proposed Sale |
10.76 |
8,442 |
90,836 |
0 |
| Powl Brian T. | Chief Commercial Officer |
Sep 28 '26 |
Sale |
10.53 |
17,020 |
179,183 |
152,249 |
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):